Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in M&A / Deals

BioAegis and Prenosis partner for inflammatory disease therapies

 April 22, 2026

Pharmaceutical Technology

BioAegis Therapeutics has entered a strategic partnership with Prenosis to advance AI-driven precision medicine for inflammatory diseases.

M&A / DealsImmunology & InflammationRead full story

Post navigation

Medicare obesity drug pilot extended after insurer pushback →
← BioAegis and Prenosis partner for inflammatory disease therapies

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com